Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
In clinical practice the gold standard method to assess BRAF status in patients with metastatic melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects the BRAF V600E mutated protein, has been developed |